Department of Infectious, Tropical Diseases & Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
StopTB Italia Onlus, Milan, Italy.
Future Microbiol. 2020 May;15:557-566. doi: 10.2217/fmb-2019-0231. Epub 2020 Jun 1.
Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.
氯法齐明（CFZ）是一种古老的疏水性苯并嗪，具有广泛的抗分枝杆菌活性，从麻风病到非结核分枝杆菌病。CFZ 具有许多优点，如良好的药代动力学特性、剂量依赖性副作用以及低廉的价格。在这篇叙述性综述中，我们评估了 CFZ 的临床开发，从潜在的作用机制开始，到副作用的范围和潜在的药物相互作用，强调了它在治疗中的当前地位以及在麻风病、非结核分枝杆菌病和耐药结核病中的未来可能用途。
